These interviews, presentations, and panel discussions took place at the BPI Theater at BIO 2024 in San Diego, CA. Centering the presentations around two key themes —  novel modalities and new technologies — enabled theater speakers and attendees to engage complex, interconnected topics that are of interest to BPI readers.

Editors Dan Stanton and Millie Nelson were on site, and their interviews and panel discussions with leading biopharmaceutical executives are also featured below.

Watch the full presentations by following the links below.

The Make-or-Buy Decision for Cell and Gene Therapy Manufacturing: Implications for Overcoming Manufacturing Bottlenecks and Challenges

The State of the Industry: Experts Discuss the Future of Biomanufacturing at BIO 2024

Improving Expression and Manufacturing of Novel Biologics

Driving Therapies Forward with the End Goal in Mind

Transitioning from Fed-Batch to Continuous Biomanufacturing Processes

Biomanufacturing Supply and Demand: Industry Trends and Projected Impacts

Strategies for Integrated Development and Manufacturing: Adapting Batch Platforms and Facilities for Multimodal Biopharmaceutical Production and Continuous Processing

Seamless Viral-Vector Technology Transfer at Any Phase: Offering Stability in Times of Change

A View of the Future for Manufacturing Viral Vectors

Overcoming Challenges of Batch Manufacturing with Fully Connected Continuous Manufacturing

What Unseen Trouble Lies Within Your Processes?

Opportunities and Challenges in Developing a Fully Connected Continuous Manufacturing Process for Biologics

The Latest Analytical Technologies and Approaches for Bioprocessing

The Ultimate Interface for Drug Discovery: How Spatial Computing and AI Agents Are Transforming How We Understand Molecules

Introducing the Next Generation of High-Performance Protein A Resin

Developing a Fully Integrated, Digitally Controlled, Intelligent Production Manufacturing Line for xRNA

Continuous Biomanufacturing for Increasing Access to Biologics

BPI Theater Interview: Ramin Baghirzade, Senior Director of Gene Therapy, Charles River Laboratories